TLR agonist combinations that stimulate Th type I polarizing responses from human neonates

Area of Science:

• Immunology
• Vaccinology
• Neonatal Research

Background:

• Millions of neonatal deaths occur annually from vaccine-preventable infectious diseases.
• Neonates exhibit an inherent Th2 immune bias, hindering effective vaccine responses.
• Current neonatal vaccines require improved immunogenicity to combat early-life infections.

Purpose of the Study:

• To develop novel neonatal vaccines by identifying TLR agonist combinations.
• To overcome the neonatal Th2 immune bias and promote a Th1-polarizing response.
• To enhance the immunogenicity of early childhood vaccines through adjuvant strategies.

Main Methods:

• Systematic stimulation of cord blood mononuclear cells with various TLR agonist combinations.
• Measurement of cytokine profiles (IL-12p70, IFN-γ, IFN-α, IL-10, IL-13, TNF-α, IL-6, IL-1β) in cell supernatants.
• Assessment of APC costimulatory markers (CD40, CD83, PD-L1) via flow cytometry and whole blood assays.

Main Results:

• TLR agonist combinations including Poly I:C, MPLA, or R848 induced robust Th1 responses (IL-12p70, IFN-γ, IFN-α).
• CpG ODN addition reduced Th1 responses, while TLR2 agonists increased Th2-biased IL-13.
• R848-containing combinations showed lower PD-L1 expression on dendritic cells compared to CpG ODN combinations.

Conclusions:

• Combination adjuvants incorporating TLR3, TLR4, and TLR7/8 agonists show promise for neonatal vaccines.
• These strategies can effectively overcome the neonatal Th2 immune bias.
• Optimized adjuvant combinations are key to improving neonatal vaccine efficacy and reducing mortality.